Protagenic Stock Plunges 17.03% Amid Merger Investigation

On May 20, 2025, Protagenic's stock experienced a significant drop of 17.03% in pre-market trading, sparking concerns among investors and analysts alike.

Halper Sadeh LLC, an investor rights law firm, has initiated an investigation into the fairness of the merger between Protagenic Therapeutics, Inc. and Phytanix Bio Inc. This investigation is focused on whether the merger complies with federal securities laws and if the board of Protagenic has fulfilled its fiduciary duties to shareholders. The firm is examining potential violations and breaches that could impact the value of Protagenic's stock.

The investigation has raised questions about the transparency and fairness of the merger process, which could have significant implications for Protagenic's future performance and investor confidence. The outcome of this investigation will be closely watched by the market, as it could influence the company's strategic direction and shareholder value.